Cryoport Announces Proposed Public Offering of Common Stock

Cryoport Announces Proposed Public Offering

IRVINE, Calif., June 19, 2019 /PRNewswire/ - Cryoport,

Inc. (Nasdaq: CYRX) (Nasdaq: CYRXW) ("Cryoport" or the "Company") today announced that it intends to offer

shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities

and Exchange Commission (the "SEC"). The offering is subject to market and other conditions, and there can be no assurance

as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cryoport also expects to

grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public

offering. All of the shares in the offering are to be sold by Cryoport.

The Company expects to use the net proceeds from the offering

of the shares for working capital, inventory development, global infrastructure buildout and facilities expansion, sales and marketing

and, potentially, acquisitions with strategic impact.

Jefferies and SVB Leerink are acting as joint book-running managers

The public offering will be made pursuant to a registration

statement on Form S-3 that was previously filed with and declared effective by the SEC. A preliminary prospectus supplement and

accompanying base prospectus relating to and describing the terms of the offering have been filed with the SEC and are available

on the SEC's website located at http://www.sec.gov or may be obtained from Jefferies, Attention: Equity Syndicate Prospectus

Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com;

or SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at 800-808-7525,

ext. 6132 or by email at syndicate@svbleerink.com. The final terms of the offering will be disclosed in a final prospectus supplement

to be filed with the SEC.

This press release shall not constitute an offer to sell or

the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in

any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of any such state or jurisdiction.

About Cryoport, Inc.

Cryoport is a global provider of temperature-controlled logistics

solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with logistics solutions for

biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR T-cells. Cryoport's solutions

are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers

et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in

the areas of vaccines and reproduction.

Forward-Looking Statements

Statements in this press release which are not purely historical,

including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans

or predictions of the future, such as: the Company's expectations regarding the completion of the public offering, its expectations

with respect to granting the underwriters a 30-day option to purchase additional shares and the anticipated use of net proceeds

from the offering, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It

is important to note that the Company's actual results could differ materially from those in any such forward-looking statements.

Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated

with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market

acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors,

including the risk factors discussed in the preliminary prospectus supplement relating to the offering and the documents incorporated

by reference therein, which include the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed with

the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release.

The Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.